These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

117 related items for PubMed ID: 32249964

  • 1. Effect of mTOR inhibitors during CMV disease in kidney transplant recipients: Results of a pilot retrospective study.
    Kaminski H, Belanger J, Mary J, Garrigue I, Acquier M, Déchanet-Merville J, Merville P, Couzi L.
    Microbiol Immunol; 2020 Jul; 64(7):520-531. PubMed ID: 32249964
    [Abstract] [Full Text] [Related]

  • 2. Preemptive anti-cytomegalovirus therapy in high-risk (donor-positive, recipient-negative cytomegalovirus serostatus) kidney transplant recipients.
    Hasegawa J, Hatakeyama S, Wakai S, Omoto K, Okumi M, Tanabe K, Mieno M, Shirakawa H.
    Int J Infect Dis; 2017 Dec; 65():50-56. PubMed ID: 28986314
    [Abstract] [Full Text] [Related]

  • 3. The influence of mTOR inhibitors on the incidence of CMV infection in high-risk donor positive-recipient negative (D+/R-) kidney transplant recipients.
    Cristelli MP, Esmeraldo RM, Pinto CM, Sandes-Freitas TV, Felipe C, Lobo CF, Viana L, Mansur J, Stopa S, Santos DWC, Grenzi PC, Aguiar WF, Tedesco-Silva H, Pestana JOM.
    Transpl Infect Dis; 2018 Aug; 20(4):e12907. PubMed ID: 29679515
    [Abstract] [Full Text] [Related]

  • 4. Fewer cytomegalovirus complications after kidney transplantation by de novo use of mTOR inhibitors in comparison to mycophenolic acid.
    Radtke J, Dietze N, Spetzler VN, Fischer L, Achilles EG, Li J, Scheidat S, Thaiss F, Nashan B, Koch M.
    Transpl Infect Dis; 2016 Feb; 18(1):79-88. PubMed ID: 26707694
    [Abstract] [Full Text] [Related]

  • 5. The effect of anti-thymocyte globulin and everolimus on the kinetics of cytomegalovirus viral load in seropositive kidney transplant recipients without prophylaxis.
    Basso G, Felipe CR, Cristelli MP, Mansur Siliano J, Viana L, Ferreira Brigido AN, Stopa Martins SB, de Castro Lima Santos DW, Aguiar WF, Tedesco-Silva Junior H, Medina-Pestana JO.
    Transpl Infect Dis; 2018 Aug; 20(4):e12919. PubMed ID: 29797676
    [Abstract] [Full Text] [Related]

  • 6. Conversion from tacrolimus-mycophenolate mofetil to tacrolimus-mTOR immunosuppression after kidney-pancreas transplantation reduces the incidence of both BK and CMV viremia.
    Knight RJ, Graviss EA, Nguyen DT, Kuten SA, Patel SJ, Gaber L, Gaber AO.
    Clin Transplant; 2018 Jun; 32(6):e13265. PubMed ID: 29676018
    [Abstract] [Full Text] [Related]

  • 7. Incidence of Cytomegalovirus DNAemia in Pediatric Kidney Transplant Recipients After Cessation of Antiviral Prophylaxis.
    Chaiyapak T, Borges K, Williams A, Banh T, Vasilevska-Ristovska J, Allen U, Parekh RS, Hébert D.
    Transplantation; 2018 Aug; 102(8):1391-1396. PubMed ID: 29377877
    [Abstract] [Full Text] [Related]

  • 8. Effect of mammalian target of rapamycin inhibitors on cytomegalovirus infection in kidney transplant recipients receiving polyclonal antilymphocyte globulins: a propensity score-matching analysis.
    Cervera C, Cofan F, Hernandez C, Soy D, Marcos MA, Sanclemente G, Bodro M, Moreno A, Diekmann F, Campistol JM, Oppenheimer F.
    Transpl Int; 2016 Nov; 29(11):1216-1225. PubMed ID: 27564469
    [Abstract] [Full Text] [Related]

  • 9. Predictive factors of spontaneous CMV DNAemia clearance in kidney transplantation.
    Noble J, Gatault P, Sautenet B, Gaudy-Graffin C, Beby-Defaux A, Thierry A, Essig M, Halimi JM, Munteanu E, Alain S, Buchler M.
    J Clin Virol; 2018 Nov; 99-100():38-43. PubMed ID: 29306112
    [Abstract] [Full Text] [Related]

  • 10. Use of maintenance therapy and incidence of recurrent Cytomegalovirus DNAemia among allogeneic hematopoietic cell transplant recipients.
    Camargo JF, Anderson AD, Rosa R, Kimble E, Komanduri KV, Morris MI.
    Transpl Infect Dis; 2019 Apr; 21(2):e13054. PubMed ID: 30689300
    [Abstract] [Full Text] [Related]

  • 11. Use of mTOR inhibitor as prophylaxis for cytomegalovirus disease after kidney transplantation: A natural experiment.
    Cristelli MP, Felipe CR, Prizmic PSS, de Azevedo VFD, Viana LA, Tavares MG, Wagner de Castro Lima Santos D, de Paula MI, Medina-Pestana JO, Tedesco-Silva Junior H.
    Clin Transplant; 2019 Oct; 33(10):e13689. PubMed ID: 31400155
    [Abstract] [Full Text] [Related]

  • 12. Incidence of cytomegalovirus infection in seropositive kidney transplant recipients treated with everolimus: A randomized, open-label, multicenter phase 4 trial.
    Kaminski H, Kamar N, Thaunat O, Bouvier N, Caillard S, Garrigue I, Anglicheau D, Rérolle JP, Le Meur Y, Durrbach A, Bachelet T, Savel H, Coueron R, Visentin J, Del Bello A, Pellegrin I, Déchanet-Merville J, Merville P, Thiébaut R, Couzi L.
    Am J Transplant; 2022 May; 22(5):1430-1441. PubMed ID: 34990047
    [Abstract] [Full Text] [Related]

  • 13. Diagnostic utility of monitoring cytomegalovirus-specific immunity by QuantiFERON-cytomegalovirus assay in kidney transplant recipients.
    Deborska-Materkowska D, Perkowska-Ptasinska A, Sadowska A, Gozdowska J, Ciszek M, Serwanska-Swietek M, Domagala P, Miszewska-Szyszkowska D, Sitarek E, Jozwik A, Kwiatkowski A, Durlik M.
    BMC Infect Dis; 2018 Apr 16; 18(1):179. PubMed ID: 29661141
    [Abstract] [Full Text] [Related]

  • 14. Impact of an ultrasensitive Cytomegalovirus quantitative nucleic acid test on Cytomegalovirus detection and therapy in renal transplant recipients.
    Beechar VB, Pouch SM, Phadke VK, Karadkhele G, Larsen CP, Woodworth MH.
    Transpl Infect Dis; 2024 Feb 16; 26(1):e14219. PubMed ID: 38158932
    [Abstract] [Full Text] [Related]

  • 15. Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation.
    Becker BN, Becker YT, Leverson GE, Simmons WD, Sollinger HW, Pirsch JD.
    Am J Kidney Dis; 2002 May 16; 39(5):1088-95. PubMed ID: 11979354
    [Abstract] [Full Text] [Related]

  • 16. Prevention strategies for cytomegalovirus disease and long-term outcomes in the high-risk transplant patient (D+/R-): experience from the RESITRA-REIPI cohort.
    Meije Y, Fortún J, Len Ó, Aguado JM, Moreno A, Cisneros JM, Gurguí M, Carratalà J, Muñoz P, Montejo M, Blanes M, Bou G, Pérez JL, Torre-Cisneros J, Ramos A, Pahissa A, Gavaldà J, Spanish Network for Research on Infection in Transplantation (RESITRA) and the Spanish Network for Research on Infectious Diseases (REIPI).
    Transpl Infect Dis; 2014 Jun 16; 16(3):387-96. PubMed ID: 24807640
    [Abstract] [Full Text] [Related]

  • 17. The use of sirolimus in patients with recurrent cytomegalovirus infection after kidney transplantation: A retrospective case series analysis.
    Shendi AM, Hung RKY, Caplin B, Griffiths P, Harber M.
    Saudi J Kidney Dis Transpl; 2019 Jun 16; 30(3):606-614. PubMed ID: 31249224
    [Abstract] [Full Text] [Related]

  • 18. Conversion to mTOR Inhibitor to Reduce the Incidence of Cytomegalovirus Recurrence in Kidney Transplant Recipients Receiving Preemptive Treatment: A Prospective, Randomized Trial.
    Viana LA, Cristelli MP, Basso G, Santos DW, Dantas MTC, Dreige YC, Requião Moura LR, Nakamura MR, Medina-Pestana J, Tedesco-Silva H.
    Transplantation; 2023 Aug 01; 107(8):1835-1845. PubMed ID: 37046380
    [Abstract] [Full Text] [Related]

  • 19. Cytomegalovirus prevention strategies in seropositive kidney transplant recipients: an insight into current clinical practice.
    Fernández-Ruiz M, Arias M, Campistol JM, Navarro D, Gómez-Huertas E, Gómez-Márquez G, Díaz JM, Hernández D, Bernal-Blanco G, Cofan F, Jimeno L, Franco-Esteve A, González E, Moreso FJ, Gómez-Alamillo C, Mendiluce A, Luna-Huerta E, Aguado JM, OPERA Study Group.
    Transpl Int; 2015 Sep 01; 28(9):1042-54. PubMed ID: 25864986
    [Abstract] [Full Text] [Related]

  • 20. Reduction in late onset cytomegalovirus primary disease after discontinuation of antiviral prophylaxis in kidney transplant recipients treated with de novo everolimus.
    Devresse A, Leruez-Ville M, Scemla A, Avettand-Fenoel V, Morin L, Lebreton X, Tinel C, Amrouche L, Lamhaut L, Timsit MO, Zuber J, Legendre C, Anglicheau D.
    Transpl Infect Dis; 2018 Apr 01; 20(2):e12846. PubMed ID: 29360195
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.